The novel compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesteryl ester transfer protein activity

Metabolism: Clinical and Experimental

Volumn 46, Issue 3, 1997, Pages 257-260

  Tsutsumi, Kazuhiko ^a   Inoue, Yasuhide ^b   Hagi, Akifumi ^b   Murase, Toshio ^b  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONATE DIETHYL ESTER; 4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID; 4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN LIPASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; HAMSTER; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN BINDING; RABBIT;

EID: 0031034028     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90250-X     Document Type: Article

References (13)

1. Gorden DJ, Rifking BM: Current concepts: High-density lipoprotein: The clinical implications of recent studies. N Engl J Med 321:1311-1316, 1989
2. Eisenberg S: High density lipoprotein metabolism. J Lipid Res 25:1017-1058, 1984
3. Eckel RH: Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic disease. N Engl J Med 320:1060-1068, 1989
4. Inazu A, Jiang X-C, Haraki T, et al: Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest 94:1872-1882, 1994
5. Tsutsumi K, Inoue Y, Shima A, et al: The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J Clin Invest 92:411-417, 1993
6. Tsutsumi K, Inoue Y, Shima A, et al: Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes 44:414-417, 1995
7. Koizumi J, Mabuchi H, Yoshimura A, et al: Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteiaemia. Atherosclerosis 58:175-186, 1985
8. Yamashita S, Matsuzawa Y, Okazaki M, et al: Small polydisperse low density lipoproteins in familial hyperalphalipoproteinaemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis 70:7-12, 1988
9. Ha YC, Barter PJ: Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol 71B:265-269, 1982
10. Murase T, Uchimura H: A selective decline of post-heparin plasma hepatic triglyceride lipase in hypothyroid rats. Metabolism 29:797-801, 1980
11. Krauss RM, Windmueller HG, Levy RI, et al: Selective measurement of two different triglyceride lipase activities in rat postheparin plasma. J Lipid Res 14:286-295, 1973
12. Kato H, Nakanishi T, Arai H, et al: Purification, microheterogeneity, and stability of human lipid transfer protein. J Biol Chem 264:4082-4087, 1989
13. Tall AR: Plasma cholesteryl ester transfer protein. J Lipid Res 34:1255-1274, 1993